In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen, Inc.

Latest From Amgen, Inc.

Digital Health Roundup: Brain Talk On Seizures, Alzheimer's, Stress, Anxiety; Medtronic's OR Report; Health Care AI; UK Guidances

In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights AI discussions at the HLTH Europe conference and an interview with Motif Neurotech's CEO Jacob Robinson. Elizabeth Orr discusses DeepWell DTx's newly launched VR game for treating stress-related hypertension and anxiety. Natasha Barrow provides an overview of Digital Mental Health Technologies regulation in the UK and Brian Bossetta reports ‘the good and bad’ from Medtronic's report on digital technologies' use in the operating room. 

Digital Health Roundup Digital Health

Japan Phase III Wins, Asian Alliances Buoy Kissei's Linzagolix

While its European licensee is preparing for an imminent launch, Kissei has also been expanding its partnerships in Asia for female health product linzagolix. A new alliance is also being sought in the US to assist with a new trial and NDA refiling there.

Women's Health Research & Development

Finance Watch: A Year After Investors Denied Infinity Merger, MEI Considers Strategic Alternatives

Restructuring Edition: Financial market conditions are improving, but gains have not stopped some companies from cutting costs or shutting down. MEI may wind down if it does not identify another strategic alternative and Aslan has begun to liquidate, while others have cut jobs.

Restructuring Business Strategies

Agenus Needs Phase III For BOT/BAL, Another Example Of Shifting Accelerated Approval Climate

The US FDA surprised some observers when it advised Agenus against filing for accelerated approval of the CTLA-4/PD-1 combination, but the agency has been cracking down on confirmatory trial requirements recently to better ensure the studies will be finished.

Cancer Review Pathway
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Abgenix
    • Amgen Astellas BioPharma K.K.
    • Amgen K.K.
    • Avidia
    • BioVex Group
    • Catherex, Inc.
    • ChemoCentryx, Inc.
    • deCODE Genetics
    • Dezima Pharma B.V.
    • Five Prime Therapeutics, Inc.
    • Ilypsa
    • Immunex Corporation
    • KAI Pharmaceuticals
    • Kirin-Amgen Inc.
    • Laboratorio Quimico Farmaceutico Bergamo Ltd
    • Micromet, Inc. (CancerVax Corporation)
    • Nuevolution AB
    • Nuevolution A/S
    • Onyx Pharmaceuticals, Inc. (Proteolix, Inc.)
    • Saga Investments LLC
    • Tularik